01.19.21 Tips For Using Bayesian Methods In Clinical Trial Designs
Clinical trials designed using Bayesian statistics are gaining prominence due to challenges raised by COVID-19. The former FDA director of biostatistics, Gregory Campbell, discusses best practices for securing regulatory approval when submitting a trial that employs Bayesian clinical trial design.
Gain some behind-the-scenes insights into the development of this new module and understand how your company can leverage East Alloy to conduct computationally intensive designs with ease, confidence, and speed.
One of the revelations of the COVID-19 pandemic is that the flexibility and potential of Bayesian designs goes far beyond the benefits connected to informed priors. This article summarizes a recent panel on COVID-19 drug discovery where biostatisticians and former regulators reflected on certain misconceptions about Bayesian methods.
12.21.20 Lilly, Care Access Take COVID Trial Directly To Patients
Introducing WCG IRB We’re combining best-in-class capabilities to raise the bar for our industry. Building on our 52-year legacy of expertise and service, our five industry-leading IRBs are now WCG IRB one unified team protecting human research participants and delivering a seamless review experience. Together at the forefront of research we are reshaping the future of ethical review with our unified experience and revolutionary new submission platform. Empowering research and advancing health.
Featured Editorial
By Ed Miseta, chief editor, Clinical Leader
Eli Lilly and Company and Care Access Research have forged a unique partnership to develop and manage a first-of-its kind decentralized, mobile trial to safeguard the health of patients in nursing homes. Lilly and Care Access will take the trial directly to patients.